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October 7, 2008:1276–8witched), however, show a statistically greater proportion of
igh-risk patients in the consistent treatment group (see Table 1 of
hite et al. [1]). Thus, similarity of the 2 groups is not a strength
f the study as suggested.
Removal of the bivalirudin plus glycoprotein (GP) IIb/IIIa
roup from this post-hoc analysis effectively removes a large
opulation that could have increased bleeding complications, and
t would be interesting to see whether the end points could be
aintained if the switch from heparin to bivalirudin plus GP
Ib/IIIa inhibitors was added to the population studied.
Bivalirudin was compared with heparin plus a GP IIb/IIIa
nhibitor. Although recommended by guidelines, in the setting
escribed, the proportion of patients being placed on GP IIb/IIIa
nhibitors in real-world practice is much lower (i.e., approximately
5% in the U.S. [2] and 5% in Australia [3]).
Although one could expect some mortality benefit in the
witched group, because of reduced bleeding over a length of time
s in the ISAR (Innovative Stratification of Arrhythmic Risk) trials
4), the cost effectiveness of bivalirudin is a critical question when
onsidering popular use.
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eply
e would like to thank Drs. Mishra and Walters for their interest
n our work (1). As they accurately point out, there were differences
n 2 of the more than 20 baseline characteristics. However,
lthough patients in the heparin plus glycoprotein IIb/IIIa inhib-
tor (GPI) group more frequently had increased creatine kinase-
yocardial band, troponin levels, or electrocardiogram changes,
ultivariate logistic regression confirmed the results of the uni-
ariate analysis. This adjusted analysis demonstrated that switch-
ng from heparin plus a GPI to bivalirudin monotherapy resulted
n similar rates of composite ischemia (odds ratio [OR]: 0.97; 95%
onfidence interval [CI]: 0.76 to 1.23; p  0.77), and significantlyess non-coronary artery bypass graft major bleeding (OR: 0.47;
5% CI: 0.34 to 0.66; p  0.0001) and net clinical events (OR:
.76; 95% CI: 0.62 to 0.94; p  0.01).
Regarding why we elected not to display the results of the
ivalirudin plus GPI group, in the main ACUITY (Acute Cath-
terization and Urgent Intervention Triage Strategy) trial (2),
ivalirudin plus GPI showed no incremental benefit over bivaliru-
in alone in terms of reducing ischemia but did result in more
leeding. Given these facts, the more expensive bivalirudin plus
PI regimen is unlikely to enter routine clinical practice and, thus,
e did not include these data in the article.
The third point Drs. Mishra and Walters make is that the
CUITY trial was designed to assess the addition of a treatment
bivalirudin) to guideline-recommended therapy. We believe that
his is the appropriate way to perform trials; it would be detrimen-
al for patients to test new treatments in the absence of guideline-
ecommended therapies.
Finally, in respect to cost effectiveness, preliminary analysis
hows bivalirudin to be very cost effective. A prospective analysis
3) showed that 30-day costs were lowest with bivalirudin mono-
herapy compared with heparin plus GPI (cost savings ranging
rom $123 per patient with bivalirudin monotherapy vs. heparin
PI administration in the catheterization laboratory to $422 per
atient with bivalirudin monotherapy vs. heparin  upstream
PI).
Thus, adjusted analysis of the switch cohort demonstrates that
he results with bivalirudin monotherapy remain consistent despite
light differences in baseline characteristics. The present study
upports the safety and efficacy of switching to bivalirudin from
nfractionated heparin or enoxaparin in moderate- and high-risk
atients with non–ST-segment elevation acute coronary syn-
romes and preserves the 50% reduction in major bleeding seen
ith bivalirudin, with comparable rates of ischemia and, thus,
mproved overall patient outcomes.
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